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Background: The role of carotid surgery for the management of restenosis after carotid endarterectomy (CEA) is
challenged by carotid artery stenting (CAS). We reviewed redo CEA in a consecutive series of patients to determine the
safety, durability, and long-term benefit associated with repeat surgical treatment for restenosis.
Methods: A consecutive series of 73 redo procedures in 72 patients (57% men) with a mean age 66 years (range, 49-81
years) was analyzed. The mean interval between prior CEA and redo CEA was 53 months (range, 8-192 months).
Operative indications included symptomatic restenosis in 28 patients (38%). A patch angioplasty was performed in 62
patients (85%). The main outcome measures included perioperative and late stroke and death, and the development of
secondary restenosis.
Results: There were no perioperative deaths or strokes. During a mean follow-up of 52 months (range, 12-144 months),
the Kaplan-Meier cumulative survival was 85% at 5 years. At 5 years, the cumulative rate of freedom from all strokes was
98%, and the freedom from ipsilateral stroke was 100%. After secondary procedures, re-recurrent stenosis>50% occurred
in 10 patients (13.7%). The cumulative freedom from re-restenosis (>50%) was 85% at 5 years. Five patients (7%) received
tertiary carotid reconstructions.
Conclusion: Repeat CEA for recurrent stenosis can be performed safely with excellent long-term protection from stroke.
These data provide a standard against which the results of CAS can be compared. (J Vasc Surg 2008;47:363-71.)The benefit of revascularization procedures for carotid
artery stenosis is hampered by the occurrence of restenosis,
which is associated with a modestly increased risk of
stroke.1,2 Restenosis after previous carotid endarterectomy
(CEA) has been detected with increasing frequency be-
cause of the use of noninvasive testing.1,2 Symptomatic
recurrent carotid stenosis has been reported to range from
0.6% to 3.6%, and asymptomatic recurrent stenosis, based
on these noninvasive studies, from 8.8% to 19%.1-3 Most
authors agree that symptomatic restenosis warrants inter-
vention, but the issue of treatment of asymptomatic reste-
noses remains controversial.4 Justification of renewed sur-
gical exploration requires that the intervention have a low
periprocedural risk and provide long-term freedom from
stroke.
Although redo CEA is an accepted treatment for recur-
rent stenosis, morbidity rates relating to surgery for reste-
nosis are reportedly higher than those of CEA for primary
lesions.5-7 As a result, virtually every carotid intervention
trial includes reoperative CEA among the high-risk inclu-
sion criteria.8 This high-risk classification, although sup-
ported in the literature, continues to be debated.9 Some
authors advocate the use of carotid angioplasty and stenting
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The reports of CAS for post-CEA restenosis published
so far are mostly single-center series that have shown good
feasibility and encouraging early results. Data on long-term
results of CAS are limited, however, and will still need to be
compared with those of redo CEA.11,12 Although the
literature is replete with articles on the perioperative results
of redo surgery,5-7,13-38 long-term outcome with objective
documentation of the patency and the occurrence of late
symptoms is relatively scarce (Table IA).
This study therefore describes our experience with redo
CEA in the management of patients with a recurrent ste-
nosis after CEA. It was undertaken to delineate the opera-
tive risk, long-term durability, and stroke-free survival ben-
efit of reoperative CEA in a contemporary surgical series in
the context of minimally invasive approaches to recurrent
cerebrovascular disease. Table IB).
METHODS
Patient selection and data collection. Our comput-
erized vascular registry was used to identify all patients
undergoing redo CEA between 1985 and January 2006
and their data were analyzed. Inclusion criteria were com-
plete data on primary and redo-surgery, complete fol-
low-up with clinical examination and duplex ultrasound
(DUS) imaging between the primary and redo surgery, and
clinical and DUS follow-up of at least 1 year after redo
surgery. Patients who had their primary surgery in another
center were included pending inclusion criteria 1 and 2.
Excluded were patients with early postoperative redo sur-
363
JOURNAL OF VASCULAR SURGERY
February 2008364 de Borst et algery (30 days), interposition bypass repair, or CEA in
conjunction with cardiac surgery. Table IC).
All patients with 70% symptomatic or 80% asymp-
tomatic stenosis were considered for surgery. Treatment
was offered only to asymptomatic patients with three or
four diseased (50% stenosis) extracranial cerebripetal ves-
sels. Specific end points analyzed included perioperative
death and stroke, late clinical outcome, and secondary
restenosis ( 50%). Table ID).
Preoperative patients characteristics. A total of 73
procedures were performed in 72 patients. Age, sex, and
preoperative cerebral symptoms were documented (Table
II). In 14 patients, primary CEA was performed elsewhere.
Patients were defined as asymptomatic in the absence of
cerebrovascular symptoms 120 days before surgery. The
mean interval from primary CEA to repeat intervention was
53 months (range, 8-192 months; Fig 1). In 17 patients
(23%), redo CEA was performed2 years of primary CEA.
Seventeen revascularization procedures (CEA or CAS) of
the contralateral side were performed in 16 patients. The
contralateral ICA was occluded in 17 patients at the time of
primary CEA and in 18 patients at redo CEA. Contralateral
subtotal stenosis of 90% to 99% was noticed in one primary
and four CEAs.
Operative procedure. All patients were operated on
Table IA. Literature data on redo carotid endarterectomy
Author Timeframe Patients, No. Procedures, No.
Stoner 1989-2002 145 153
Cho 1990-2000 64 66
Abou-Zamzam 1990-2000 56 56
O’Hara 1989-1999 199 206
AbuRahma 1991-1998 121 124
Archie Jr 1981-1999 66 69
Gorlitzer 1992-1998 41 42
Hill 1993-1998 40 40
Rockman 1980-1996 74 82
Dillavou 1980-1998 27 27
Hobson 1989-1996 14 16
Munn 1988-1997 40 43
Ballinger 1984-1995 67 70
Mansour 1976-1996 69 82
O’Donnell 1983-1994 44 48
Rosenthal NS 31 31
Coyle 1983-1992 69 69
AbuRahma 1988-1993 46 46
Meyer 1972-1992 82 92
Gagne 1970-1991 42 47
Treiman 1974-1991 162 162
Gagne 1970-1988 29 29
Nitzberg 1961-1986 27 29
Kazmers 1979-1986 14 14
Bartlett 1957-1985 99 116
Piepgras 1972-1984 51 57
Das 1979-1983 61 65
Rapp 1957-1984 90 109
Cossman 8-y period 14 16
Hertzer 1958-1978 15 16
CEA, Carotid endarterectomy; NS, not specified.under general anesthesia by an experienced vascular sur-geon or by a specialist vascular trainee under supervision.
The decision for redo CEA, redo CEA with patch angio-
plasty, or patch angioplasty alone was determined by oper-
ative findings. Technical details of intraoperative monitor-
ing have been described previously.39 Before cross-
clamping, an intravenous injection of heparin (5000 IU)
was administered; protamine reversal was not used. Preop-
eratively, patients were started on 100 mg of aspirin daily,
or 225 mg of Asasantine (combined aspirin and dipyridam-
ole, Boehringer Ingelheim Pharmaceuticals, Ingelheim,
Germany) twice daily, which was continued postopera-
tively.
Follow-up. After surgery, patients had a clinical and
DUS follow-up at 1 day, 3 and 12 months, and yearly
thereafter. Five categories of stenosis were defined: 0% to
49%, 50% to 69%, 70% to 89%, 90% to 99%, and occlusion.
Recurrent stenosis was defined as an stenosis of 50%.
Criteria for defining a stenosis of 50% included peak systolic
velocity 125 cm/s. After redo surgery, patients re-en-
tered the carotid surveillance program.
Outcome. Before and after repeat CEA, patients were
evaluated by an independent neurologist. Any new neuro-
logic deficit lasting for 24 hours in the first 30 days was
classified as a stroke. Major stroke was defined as a persis-
tent and disabling neurologic deficit that was present at the
e, %
Age
Primary Clos
Interval
Year Range Year Range
6 69  1.3 NS 68 73 3-240
2 68.2 38-84 17 77.5 1-292
7 67 51-83 55 78 1-297
6 68 47-86 NS NS NS
9 70.1 52-81 0 57.8 7-182
4 68  8.5 NS 20 75  57 NS
1 66.6 48-85 NS 60 3-276
S 72  8 42-93 NS 72 5-252
3 67.5 41-85 NS 53 2-163
2 67 55-79 85 55 5-148
0 64.5 NS 44 NS NS
5 65 51-85 81 47.3 NS
0 67.9 40-84 55 78.1 1-240
8 66  7.7 NS NS 65 3-361
5 64.5 NS NS 45.4 NS
6 59.9 NS NS 73.1 11-168
2 66.1 51-81 NS 83 5-312
2 65.5 43-79 NS 67 NS
2 NS NS 49 NS NS
4 65.9 44-85 7 NS NS
0 65 35-84 NS NS NS
6 64.5 48-76 10 66 1-173
2 63.8 46-73 NS 50.2 2-226
0 62  9.3 46-78 NS 66.3 8-165
S NS NS NS NS NS
0 NS NS 55 NS NS
4 NS NS NS 42 3-194
S NS NS NS NS 1-180
1 60 NS NS NS NS
3 58.6 47-69 NS 45 7-156Mal
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7time of discharge. Minor stroke was defined as a persistent
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time of discharge. Cranial nerve injury was scored when
symptoms prompted further investigation, and nerve injury
was confirmed by clinical (otolaryngologic) evaluation.
Periprocedural hematoma was defined as any bleeding
needing re-exploration or transfusion.
Statistical analysis. Data were analyzed using SPSS
12.0 software (SPSS Inc, Chicago, Ill). Actuarial survival
analysis was performed by using Kaplan-Meier life tables. A
value of P .05 (log-rank) was considered significant for all
statistical analyses.
RESULTS
Seven patients presented with perioperative morbidity,
consisting of myocardial infarction in 1, cranial nerve injury
in 1, perioperative transient ischemic (TIA) attack in 2, and
bleeding complications that required re-exploration in 3
patients. Repeat CEA with patch angioplasty was the most
common procedure performed (Table III). There were no
operative deaths and no operative strokes (Table IV).
Symptom-free survival. After redo surgery, eight late
deaths occurred during a mean follow-up of 52 months
(range, 12-144 months; Fig 2). Causes of death were
cardiac in 5 patients, pulmonary in 1, malignancy in 1, and
Table IB. Literature data on redo carotid endarterectomy
Author
Early redo
2 y, %
Asymptomatic,
%
Redo
patch, %
Stoner 41 64 93
Cho NS 50 85
Abou-Zamzam 23 27 55
O’Hara NS 57 94
AbuRahma 26 58 NS
Archie Jr NS 48 86
Gorlitzer NS 40 86
Hill 42 50 64
Rockman NS 42 57
Dillavou 33 48 85
Hobson NS 44 75
Munn 56 42 70
Ballinger NS 35 74
Mansour NS 34 74
O’Donnell 27 44 NS
Rosenthal 16 16 97
Coyle NS 46 87
AbuRahma NS 28 94
Meyer NS 7 NS
Gagne 25 27 86
Treiman 20 7 65
Gagne 27 21 100
Nitzberg 56 35 67
Kazmers 14 0 93
Bartlett 40 30 1
Piepgras 25 9 89
Das 43 51 91
Rapp NS 27 43
Cossman 69 21 NS
Hertzer 56 NS 94
CEA, Carotid endarterectomy; NS, not specified.undetermined in 1. Kaplan-Meier estimate for the proba-bility of overall survival was 85% at 5 years. Two patients
were lost to follow-up. Three patients became symptomatic
during follow-up. Late stroke occurred in one patient
(1.4%) (Table IV) who had a symptomatic contralateral
occlusion 3 years after redo CEA. One patient had repeat-
ing TIAs at 23 months, and one patient had a vertebral
basilar artery insufficiency (VBI) at 46 months of follow-
up. The all-cerebral symptom-free survival was 93% at 5
years (Fig 3).
At 5 years, the probability of freedom from any stroke
was 98%, and the probability of freedom from ipsilateral
stroke was 100%. No patients had a clinically evident late
TIA or stroke after redo CEA without the evidence of
secondary recurrent stenosis. The patients’ symptom status
at the time of recurrent stenosis did not influence the
outcome after redo surgery.
Secondary restenosis. All DUS scans obtained 3
months after CEA demonstrated patent internal carotid
arteries (ICA) and velocity spectra of 50% stenosis. Sec-
ondary restenosis was detected in 10 patients (13.7%).
Three of these patients were symptomatic (1 contralateral
stroke, 1 repeating TIA, 1 VBI). There were no ipsilateral
occlusions during follow-up.
Kaplan-Meier estimates for freedom from secondary
tinued)
Perioperative Cranial nerve injury
h, % Stroke, % TIA, % MI, % % Permanent, %
1.9 0 0 1.3 0.6
3.1 3.1 5 6 1.5
5.4 NS 1.8 1.7 0
3.4 NS 1 1 0
4.8 4 0 17 1.6
2.9 1.4 0 4.3 0
2.4 4.8 0 14.3 NS
0 NS 5 8 0
3.7 1.2 0 1.2 0
0 0 3.7 NS 0
0 0 0 6.2 6.2
0 0 2.3 9.3 0
1.4 NS 1.4 NS 2.8
4.8 1.2 2 7.3 1.2
2.1 4.2 6.3 19 0
0 3.2 0 6.4 6.4
1.4 NS 2.9 0 0
7 0 0 7.5 5
5.4 4.3 2.2 NS NS
0 6.8 0 4.5 2.2
1.9 0 0 2.4 0
0 10.3 0 3.4 3.4
3.4 6.8 3.4 17 0
0 0 0 14 7.1
4.3 2 0 17 NS
6 2 2 NS NS
1.5 0 0 9.2 1.6
3 3 0 15 NS
S NS NS NS NS NS
0 6.3 0 NS NS(con
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0restenosis were 85 % at 5 years and 73% at 10 years (Fig 4).
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tertiary carotid reconstruction (1 venous bypass, 1 polytet-
rafluoroethylene bypass, 3 CEAs with patch). Kaplan-
Meier estimates for reintervention-free survival were 94% at
5 years and 74% at 10 years (Fig 5). Indications for a third
operation included repeating TIAs in one patient, VBI in
one patient, and asymptomatic high-grade stenosis with
four-vessel disease in three patients. Because the actual time
of restenosis was likely to have occurred before its detec-
tion, the actual freedom from restenosis estimates is likely
to be lower than calculated by the date of DUS detection.
Localization. Restenosis occurred in the previous
CEA site in 83%, proximal to the CEA site in 3%, distally in
the ICA in 11%, and both proximal and distal to but not
within the site of CEA in 3%. Of the 10 patients with
secondary restenosis, four of five ICA re-recurrent stenoses
had original recurrent stenosis in the ICA, whereas two of
the three common carotid artery (CCA) re-recurrences had
original recurrent stenosis in the CCA and one in the ICA.
DISCUSSION
Our results demonstrate that redo CEA for recurrent
carotid stenosis (1) can be performed with an acceptably
low perioperative stroke and death rate, (2) has a high
Table IC. Literature data on redo carotid endarterectomy
Author Hematoma , %
Follow-up
Month Range
Stoner 3.2 52.8 1-152
Cho 3 51.6 3-155
Abou-Zamzam NS 29 1-116
O’Hara NS 51.6 1-122
AbuRahma 0.8 49 NS
Archie Jr NS 50 1-180
Gorlitzer 4.8 NS NS
Hill 0 14 1-52
Rockman NS 35 1-150
Dillavou 3.7 54 6-152
Hobson NS 30 NS
Munn 4.6 34 3-108
Ballinger 1.4 48 1-162
Mansour 2.4 NS NS
O’Donnell 4.2 NS NS
Rosenthal NS 39.8 NS
Coyle 8.7 57 1-132
AbuRahma NS 30.9 6-73
Meyer NS NS NS
Gagne 2.2 54 9-202
Treiman 1 64 2-149
Gagne NS 50 11-182
Nitzberg 3.4 47.2 1-127
Kazmers NS 27.4 4-87
Bartlett 3.4 NS NS
Piepgras NS NS NS
Das NS 23 1-137
Rapp NS NS NS
Cossman NS NS NS
Hertzer 0 18 1 to 70
CEA, Carotid endarterectomy; NS, not specified.long-term stroke-free rate, and (3) has a high long-termsecondary restenosis-free rate. The occurrence of another
ipsilateral recurrent stenosis that requires a third carotid
operation (7%) is rare.
Guidelines for primary CEA define an acceptable
stroke/death rate of 6% for symptomatic patients and
3% for asymptomatic patients.40 The upper limit of ac-
ceptable stroke/death rate for reoperative CEA has been
defined to be 10%.41 The low rate of perioperative major
adverse outcome in this study is echoed by other reopera-
tive series, with stroke/death rates noted between 0% and
7% (Table I). Our rate of freedom from late stroke is also
high and consistent with the literature, with operative
indications not different from others (Table I). The claimed
higher complication rate after redo CEA is particularly
related to postoperative cranial nerve palsies but could not
be confirmed in our series. In the literature, cranial nerve
injuries are reported to range from 1% to 17% (Table I),
where it shows that most reported injuries are transient and
without clinical significance. Reoperation for neck hema-
toma is only occasionally required.
Redo carotid surgery has been extensively reported, but
only a few reports describe a clear long-term evalua-
tion.13,14,17,19 Our results are consistent with the experience
tinued)
Late stroke
Occlusion in
Stroke-free rate
Ipsilat-contralat 5 y, % 10 y, %
NS NS 96 NS
4 vs 1 1 92 74
1 vs 0 1 90 NS
NS 7 92 NS
NS NS 82 NS
2 vs 1 vs NS 90 86
NS NS NS NS
0 NS NS NS
0 5 NS NS
3 vs 0 NS 85 65
1 vs 0 1 NS NS
1 vs 0 1 87 NS
2 vs 4 NS 93.6 NS
NS NS 92.3 NS
NS NS NS NS
irr irr irr irr
1 vs 0 NS NS NS
0 NS 85 NS
NS NS NS NS
1 vs 0 5 96 96
5 vs 0 1 NS NS
1 vs 0 3 NS NS
1 vs 1 NS 83.3 83.3
0 NS NS NS
NS NS NS NS
NS 1 NS NS
NS NS NS NS
NS NS NS NS
NS NS NS NS
0 0 NS NS(con
%
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0of other investigators that focus on durability (Table I).
CEA, Carotid endarterectomy; NS, not specified.
CEA, Carotid endarterectomy; VBI, vertebral basilar artery insufficiency.
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Volume 47, Number 2 de Borst et al 367Fig 1. Time of development of restenosis after 73 primary carotidTable ID. Literature data on redo carotid endarterectomy (continued)
Author
Restenosis
Symptomatic
Restenosis-free
survival Tertiary
procedures,
%
Interposition
bypass, %DEF, %  50% 70% 5 y 10 y
Stoner 50% 9.2 1.3 0 NS NS 0 0
Cho 80% 9 3 3 94 86 2 12
Abou-Zamzam 80% 5.4 5.4 NS 93 NS 3.6 45
O’Hara 60% 10 3 NS 83 NS NS 4
AbuRahma 50% 5.6 1.6 NS 95 NS 0 0
Archie Jr 50% 13 4 1.4 88 68 4.3 13
Gorlitzer NS NS NS NS NS NS NS 6
Hill 50% 5 5 NS NS NS 0 50
Rockman 50% 4.8 NS 3.6 83.5 NS 4.9 42.7
Dillavou 50% 21 8.7 3.7 NS NS 7.4 7.5
Hobson NS 6.2 0 0 NS NS 0 25
Munn 50% 4.6 NS 4.6 NS NS 2.3 23
Ballinger NS NS NS NS NS NS 0 10
Mansour NS 8 NS NS 92.3 NS 0 24
O’Donnell NS NS NS NS NS NS 0 NS
Rosenthal irr irr irr irr irr NS 100 3
Coyle NS NS NS NS NS NS 0 0
AbuRahma 50% 2 0 2.2 NS NS 2.2 0
Meyer NS NS NS NS NS NS NS 24
Gagne 50% 10.3 6.9 2.1 NS NS 7 13
Treiman 50% 22 15 20 NS NS 20 35
Gagne 50% 21 5.3 6.9 NS NS 11 0
Nitzberg 50% 8.3 0 0 NS NS 3.4 NS
Kazmers 50% 7.1 0 0 NS NS 14 7
Bartlett NS 5 NS NS 94 NS NS 5
Piepgras NS NS NS NS NS NS NS 10
Das NS NS NS NS NS NS NS 5
Rapp NS NS NS NS NS NS NS 9
Cossman NS NS NS NS NS NS NS 0
Hertzer NS NS NS NS NS NS NS 6endarterectomies.Table II. Patient characteristics of present series of 73
carotid endarterectomies
Demographics No. %
Patients 72
Age, mean y (redo CEA) 66
Male sex 41 56
Procedures 73
Left 36 49
Asymptomatic at first CEA 22 30
Symptomatic at first CEA 51 70
Stroke (minor/major) 9(7/2)
Transient ischemic attack 30
Amaurosis fugax 9
VBI 3
Asymptomatic at redo CEA 45 60
Symptomatic at redo CEA 28 40
Stroke (minor/major) 6(4/2)
Transient ischemic attack 15
Amaurosis fugax 6
VBI 1
Contralateral occlusion
At first CEA 17 23
At redo CEA 18 25
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ongoing thrombogenesis that begins immediately after
blood flow is restored across the endarterectomized sur-
face.42 The early lesion is subsequently formed as the
thrombus organizes and smooth muscle cell ingrowth oc-
curs, creating a supposed morphologic distinction between
early (2 years of CEA) and late (2 years) recurrent
carotid disease.43 Later studies supported the contention
that early and late recurrent lesions are truly the same, that
is, myointimal hyperplasia (MIH), which undergoes pro-
gressive atherosclerotic change that is just observed at
different time points along a continuum.42
Early MIH lesions tend to be smooth, with little em-
bolic potential,44 although others found half of patients
with MIH lesions have a symptomatic presentation.14,29 In
17 of our patients, reoperation was24 months of primary
Table III. Surgical characteristics of present series of 73
carotid endarterectomies
Characteristic No. %
Shunt at first CEA 17 23
Patch at first CEA 26 36
Venous 17
Prosthetic 9
Shunt at redo CEA 32 44
CEA  patch at redo CEA 56 77
CEA without patch 11 15
Patch angioplasty alone 6 8
Total venous patch 43
Total prosthetic patch 19
Time between CEA and redo CEA 53
Contralateral CEA/CAS 11 15
CEA, Carotid endarterectomy; CAS, carotid artery stenting.
Table IV. Perioperative and long-term clinical outcome
after 73 redo carotid endarterectomies
Outcomes No. or mean % or range
Perioperative
Mortality 0 0
Stroke 0 0
Transient ischemic attack 2 2.8
Myocardial infarction 1 1.4
Postoperative
Hematoma 3 4.1
Nerve injury 1 1.4
Long-term clinical
outcome
Mortality 8 11
All stroke 1 1.4
Ipsilateral stroke 0 0
Transient ischemic attack 1 1.4
VBI 1 1.4
Durability
Restenosis 10 13.7
Tertiary CEA 5 6.8
Time to tertiary CEA, y 5.4 3-8
CEA, Carotid endarterectomy; VBI, vertebral basilar artery insufficiency.CEA and likely represented treatment of MIH lesions.Most patients who become symptomatic owing to a recur-
rent carotid stenosis do so on the basis of a hemodynamic
flow-related mechanism.44 A systematic review in 1998
concluded that the risk of restenosis after CEA was 10% in
the first year, 3% in the second year, and only 1% yearly
thereafter. The risk of stroke arising from a restenosis was
Fig 2. Survival after redo carotid endarterectomy. The Kaplan-
Meier estimate for probability of overall survival was 85% at 5 years
(SE, 0.051). The number of patients remaining was 73, 57, 36, 22,
9, 3, and 0, at 2, 4, 6, 8, 10, and 12 years of follow-up, respectively.
Fig 3. All symptom-free survival after redo carotid endarterec-
tomy. The Kaplan-Meier estimate was 93% at 5 years (SE, 0.0372).
The number of patients remaining was 73, 57, 36, 22, 9, 3, and 0,
at 2, 4, 6, 8, 10, and 12 years of follow-up, respectively.highly variable, from 0.1 to 10%.1We and others found that
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redo CEA without the evidence of secondary recurrent
stenosis.19 On the other hand, the incidence of restenosis is
surely not always associated with a parallel increase in late
Fig 4. Restenosis-free (50%) survival after redo carotid endar-
terectomy. The Kaplan-Meier estimates were 85% at 5 years (SE,
0.0507) and 73% at 10 years (SE, 0.0952). The number of patients
remaining was 73, 57, 36, 22, 9, 3, and 0, at 2, 4, 6, 8, 10, and 12
years of follow-up, respectively.
Fig 5. Reintervention-free survival after redo carotid endarterec-
tomy. The Kaplan-Meier estimates were 94% at 5 years (SE,
0.0336) and 74% at 10 years (SE, 0.1077). The number of patients
remaining were 73, 57, 36, 22, 9, 3, and 0, at 2, 4, 6, 8, 10, and 12
years of follow-up, respectively.stroke.45In those instances in which a recurrent lesion becomes
symptomatic, the management algorithm is straightfor-
ward: most surgeons consider this an indication for inter-
vention. Unfortunately, the appropriate management of
asymptomatic patients remains unclear.2,4,9 Some authors
assume that an asymptomatic recurrent stenosis confers an
equivalent stroke risk to primary atherosclerotic lesions.
Operative practice is usually justified by the results of the
Asymptomatic Carotid Atherosclerosis Study (ACAS), and
Asymptomatic Carotid Surgery Trial (ACST).46,47 In a
large nonrandomized series of 401 redo CEAs, the periop-
erative death/stroke risk was 5.7%. This might probably be
a better reflection of true practice. Authors with complica-
tion rates 4% in asymptomatic patients therefore cannot
simply extrapolate the landmark trial data to justify inter-
vention. Existing guidelines41 should no longer be applied
but critically revised instead.
Currently, we have no accurate way to differentiate
which lesions will cause a stroke and which will not. There-
fore, it is still our policy to reoperate on symptomatic
restenosis (70%) and on asymptomatic restenosis 80%
in patients with three or four diseased (50% stenosis)
extracranial cerebripetal vessels or a contralateral occlusion.
With a low perioperative complication rate, the risk/benefit
ratio with this approach will remain appropriate.
The site of recurrent stenosis is primarily at the ends of
or within the confines of the original CEA site.17,19,21,23,26
Most restenotic lesions (70%) are localized in the origin of
the ICA.3,32,48 In agreement with these findings, our re-
sults and pooled data from four reports that provided
location data17,21,23,43 counted a 30% incidence of major
restenosis being located in the distal CCA. Some regions of
the artery wall are exposed simultaneously to low wall shear
stress and high mechanical stress (pulsatile flow), and these
regions correspond to areas where atherosclerotic plaque
develops,49 making the carotid bulb a focus for disease.50
Single-center nonrandomized reports on the treatment
of recurrent stenosis have claimed comparable periopera-
tive outcomes for CAS and redo CEA.44,51 CAS, although
relatively safe in the short-term, has shown limitations in its
durability.12,13 Currently, there are no completed studies
with sufficient power to determine significant differences
between treatment with CEA and CAS for this condition.
The only way to compare one treatment with the other
would be with a randomized, controlled, multicenter trial.
In the 25 years since the publication by Stoney, 29
studies on redo CEA have been published with varying
sample sizes (Table I). There are only six reports of 100
procedures,6,13,16,30,33,36 10 reports of 50 to 99 proce-
dures,7,14,15,17,19,23,24,27,34,35 and 14 reports of 49
procedures.5,18,20-22,25,26,28,29,31,32,37,38 The reported
30-day stroke and death rates range from 0% to 5.4% (Table
I). The most important flaw of most of these reports is the
lack of follow-up. A true meta-analysis of available data-
bases with respect to restenosis is probably invalid because
the studies were not prospectively randomized nor were
they homogenous with respect to definition of restenosis
and type of reconstruction.
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tive treatment of recurrent carotid artery stenosis depend-
ing on the pathology and the number of previous proce-
dures. The traditional surgical approach has been repeat
CEA with patch closure, with the incision and principles of
exposure being the same as for a primary CEA. Carotid
resection with the placement of an interposition graft is
another surgical option.19,30 In our opinion, interposition
grafting is a distinct procedure; therefore, it was an exclu-
sion criterion. In the present series, however, two patients
with secondary recurrent stenosis received an interposition
graft for tertiary revascularization.
A frequently raised question about patients requiring
recurrent carotid artery operations is the role of primary
reconstruction on the incidence of reoperation. The pre-
ponderance of data at least indicate that restenosis rates are
generally lower with patch closure of the arteriotomy than
with primary closure.3 More than 85% of the operations
that were reviewed in this series consisted of redo CEAwith
vein patch angioplasty or patch angioplasty alone.
Analysis of these data is retrospective and suffers from
well-known limitations. The registry was not designed to
tell us about the perioperative stroke and death risk of the
patients who were screened but did not have redo CEA.
Two patents were lost to follow-up and may have had a
recurrence of the stenosis or an occlusion that was symp-
tomatic, unrecognized, or treated elsewhere. It is a single-
center analysis with operative results from several surgeons
during a 20-year period; however, it is a consecutive series
with excellent results from a large vascular training center
and provides insight in an important topic in this endovas-
cular era.
CONCLUSION
This study clearly demonstrates that redo CEA can be
performed with acceptable stroke and death rates. Redo
carotid operation is a durable and effective means of stroke
prevention with good long-term patency. Our results do
not support the contention that patients who require reop-
erative CEA constitute a “high-risk” subgroup in whom
reoperative therapy should be avoided. Therefore, in our
opinion it is still the standard against which alternative
treatments should be judged.
We acknowledge Henk Mauser, MD, Department of
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